Efficacy and safety of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in patients with stage IIIB/C and IVMIa melanoma: Subanalysis of the phase III OPTiM trial

OncoTargets and Therapy

Volumn 9, Issue , 2016, Pages 7081-7093

  Harrington, Kevin J ^a   Andtbacka, Robert H I ^b   Collichio, Frances ^c   Downey, Gerald ^d   Chen, Lisa ^e   Szabo, Zsolt ^e   Kaufman, Howard L ^f  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b UNIVERSITY OF UTAH   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d AMGEN LTD   (United Kingdom)

^e AMGEN INC   (United States)

^f RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

Author keywords

Benefit risk; Clinical trial; Durable response rate; Immunotherapy; Oncolytic virus; Talimogene laherparepvec

Indexed keywords

EID: 84996635693     PISSN: None     EISSN: 11786930     Source Type: Journal    
DOI: 10.2147/OTT.S115245     Document Type: Article

References (33)

1. Workenhe ST, Mossman KL. Oncolytic virotherapy and immunogenic cancer cell death: sharpening the sword for improved cancer treatment strategies. Mol Ther. 2014;22(2):251-256.
2. Chiocca EA, Rabkin SD. Oncolytic viruses and their application to cancer immunotherapy. Cancer Immunol Res. 2014;2(4):295-300.
3. United States Food and Drug Administration [webpage on the Internet]. Food and Drug Administration (FDA) Approves First-of-Its-Kind Product for the Treatment of Melanoma. 2015. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm469571.htm. Accessed December 1, 2015.
4. European Medicines Agency. The Committee for Medicinal Products for Human Use (CHMP) Summary of Opinion for Imlygic. 2015. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/002771/WC500195907.pdf. Accessed December 1, 2015.
5. Ledford H. Cancer-fighting viruses win approval. Nature. 2015;526(7575):622-623.
6. Andtbacka RH, Kaufman HL, Collichio F, et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol. 2015;33(25):2780-2788.
7. Liu BL, Robinson M, Han ZQ, et al. ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Ther. 2003;10(4):292-303.
8. Hu JC, Coffin RS, Davis CJ, et al. A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor. Clin Cancer Res. 2006;12(22):6737-6747.
9. Senzer NN, Kaufman HL, Amatruda T, et al. Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J Clin Oncol. 2009;27(34):5763-5771.
10. Cook RJ, Sackett DL. The number needed to treat: a clinically useful measure of treatment effect. BMJ. 1995;310(6977):452-454.
11. Schulzer M, Mancini GB. ‘Unqualified success’ and ‘unmitigated failure’: number-needed-to-treat-related concepts for assessing treatment efficacy in the presence of treatment-induced adverse events. Int J Epidemiol. 1996;25(4):704-712.
12. World Health Organization. World Health Organization (WHO) Handbook for Reporting Results of Cancer Treatment. Geneva: World Health Organization; 1979.
13. Bacik J, Mazumdar M, Murphy BA, et al. The functional assessment of cancer therapy-BRM (FACT-BRM): a new tool for the assessment of quality of life in patients treated with biologic response modifiers. Qual Life Res. 2004;13(1):137-154.
14. Yost KJ, Sorensen MV, Hahn EA, Glendenning GA, Gnanasakthy A, Cella D. Using multiple anchor- and distribution-based estimates to evaluate clinically meaningful change on the functional assessment of cancer therapy-biologic response modifiers (FACT-BRM) instrument. Value Health. 2005;8(2):117-127.
15. Anderson JR, Cain KC, Gelber RD. Analysis of survival by tumor response and other comparisons of time-to-event by outcome variables. J Clin Oncol. 2008;26(24):3913-3915.
16. Andtbacka RHI, Kaufman HL, Collichio FA, et al. Reduced risk of developing visceral or bone metastasis in patients with stages IIIB, IIIC, and IVM1a melanoma treated with talimogene laherparepvec versus GM-CSF. Poster presented at: Society for Melanoma Research Congress. San Francisco, CA: 2015.
17. Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711-723.
18. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(1):23-34.
19. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364(26):2507-2516.
20. Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372(4):320-330.
21. Robert C, Schachter J, Long GV, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372(26):2521-2532.
22. Bedikian AY, Johnson MM, Warneke CL, et al. Does complete response to systemic therapy in patients with stage IV melanoma translate into long-term survival? Melanoma Res. 2011;21(1):84-90.
23. Hauschild A, Grob JJ, Demidov LV, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012;380(9839):358-365.
24. Larkin J, Del Vecchio M, Ascierto PA, et al. Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study. Lancet Oncol. 2014;15(4):436-444.
25. Allison KH, Sledge GW. Heterogeneity and cancer. Oncology (Williston Park). 2014;28(9):772-778.
26. Alsaggar M, Yao Q, Cai H, Liu D. Differential growth and responsiveness to cancer therapy of tumor cells in different environments. Clin Exp Metastasis. 2016;33(2):115-124.
27. Kaufman HL, Kim DW, DeRaffele G, Mitcham J, Coffin RS, Kim-Schulze S. Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma. Ann Surg Oncol. 2010;17(3):718-730.
28. Chang CJ, Tai KF, Roffler S, Hwang LH. The immunization site of cytokine-secreting tumor cell vaccines influences the trafficking of tumor-specific T lymphocytes and antitumor efficacy against regional tumors. J Immunol. 2004;173(10):6025-6032.
29. Kaufman H, Amatruda T, Nemunaitis JJ, et al. Tumor size and clinical outcomes in melanoma patients (MEL pts) treated with talimogene laherparepvec (T-VEC). Poster presented at: American Society of Clinical Oncology Annual Meeting. (Chap. Chicago, IL). 2015.
30. Long GV, Dummer R, Ribas A, et al. Efficacy analysis of MASTERKEY-265 phase 1b study of talimogene laherparepvec (T-VEC) and pembrolizumab (pembro) for unresectable stage IIIB-IV melanoma. Poster presented at: American Society of Clinical Oncology Annual Meeting. Chicago, IL: 2016.
31. Coit DG, Thompson JA, Algazi A, et al. Melanoma, version 2. 2016, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2016;14(4):450-473.
32. Puzanov I, Milhem MM, Minor D, et al. Talimogene laherparepvec in combination with ipilimumab in previously untreated, unresectable stage IIIB-IV melanoma. J Clin Oncol. 2016;34(22):2619-2626.
33. European Medicines Agency. The Committee for Medicinal Products for Human Use (CHMP) Assessment Report for Imlygic. 2015. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002771/WC500201082.pdf. Accessed March 1, 2016.